Embecta (EMBC)

Embecta became an independent public company after being separated from Becton, Dickinson and Company, giving it a long operating heritage in injection-related devices while narrowing its focus to diabetes. Its products are used across retail and institutional healthcare settings, including pharmacies, hospitals, clinics, and long-term care environments. The company also offers a proprietary digital application intended to help people manage aspects of their diabetes routines, complementing its physical device portfolio.

Embecta primarily sells through wholesalers and distributors, which then supply retail channels, healthcare institutions, and other points of care. This distribution model gives the company broad reach while making relationships with channel partners, payers, and healthcare systems important to its performance. The United States accounts for the majority of revenue, although the company serves international markets as well.

In addition to its branded diabetes products, Embecta provides contract manufacturing services. Its investment case is shaped by the large global diabetes population, the durability of insulin delivery demand, pricing and reimbursement trends, and the company’s ability to defend its position in a competitive medical device market.